|
|||
|
Multiple Sclerosis Info
Search
This Month
|
Wednesday, February 20
Rituxamab – Effective Against MS in Phase II Trial
by
multiplesclerosis
on Wed 20 Feb 2008 08:33 AM CST
Two doses of rituximab (Rituxan) diminished relapsing-remitting multiple sclerosis lesions and clinical symptoms for nearly a year, researchers more »
Tuesday, February 19
Eli Lilly and BioMS Medical's multiple sclerosis drug MBP8298.
by
multiplesclerosis
on Tue 19 Feb 2008 08:53 AM CST
MBP8298 is currently being evaluated in two pivotal Phase III clinical trials in secondary progressive MS (SPMS) and one Phase II trial in relapsing-remitting MS (RRMS). BioMS will more »
Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis
by
multiplesclerosis
on Tue 19 Feb 2008 03:00 AM CST
To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of more »
Sunday, February 17
A Randomized Clinical Trial for RRMS Drugs
by
multiplesclerosis
on Sun 17 Feb 2008 12:00 AM CST
This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than more »
Saturday, February 16
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
by
multiplesclerosis
on Sat 16 Feb 2008 09:04 AM CST
There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and more »
Understanding Clinical Trials 2 of 2
by
multiplesclerosis
on Sat 16 Feb 2008 12:00 AM CST
Every clinical trial in the U.S. must be approved and monitored by an Institutional Review Board (IRB) to make sure the risks are more »
Friday, February 15
Understanding Clinical Trials 1 of 2
by
multiplesclerosis
on Fri 15 Feb 2008 12:00 AM CST
Choosing to participate in a clinical trial is an important personal decision. The following frequently asked questions provide detailed information about clinical trials. In addition, it is often helpful more »
Saturday, February 2
ATX-MS-1467 - Positive Immunological data in Secondary Progressive Multiple Sclerosis
by
multiplesclerosis
on Sat 02 Feb 2008 08:00 AM CST
Apitope Technology (Bristol) Ltd., the developer of peptide-based therapies for autoimmune diseases and allergy, announces today final results of a Phase I/IIa clinical trial of ATX-MS-1467 to treat Multiple Sclerosis (MS). Immunological analyses showed a significant down more »
|
||
